IVD Reagents Market - Global Forecast to 2029
商品番号 : SMB-70277
| 出版社 | MarketsandMarkets |
| 出版年月 | 2024年12月 |
| ページ数 | 424 |
| 図表数 | 595 |
| 価格タイプ | シングルユーザライセンス |
| 価格 | USD 4,950 |
| 種別 | 英文調査報告書 |
Report Overview
The global IVD reagents market is valued at an estimated 87.41 billion in 2029 and is projected to reach USD 60.45 billion by 2024, at a CAGR of 7.7% during the forecast period. The increasing adoption of IVD technologies has led to a growing need of IVD reagents. The demand for IVD reagents is therefore expected to increase as new diagnostic technologies are getting FDA, EMA approvals from regulatory bodies.
世界のIVD（体外診断用医療機器）用試薬市場は2029年に推定874億1,000万米ドルと評価され、予測期間中のCAGRは7.7%で、2024年までに604億5,000万米ドルに達すると予測されています。
“The oligonucleotide segment is projected to witness the highest growth rate in the IVD reagents market, by type, during the forecast period.”
Based on type, the IVD reagents market is segmented into antibodies, antigen, purified proteins, and peptides, oligonucleotides, nucleic acid probes, and other IVD reagents. The growing adoption of PCR-based tests in diagnostics has boosted the demand for oligonucleotide in the IVD reagents market. Oligonucleotides have wide range of applications in infectious diseases and genetic testing.
“The infectious disease segment to witness the highest share in the IVD reagents market, in 2023, by application”
Based on application, the IVD reagents market is segmented into infectious diseases, oncological applications, endocrinological applications, cardiological applications, blood screening, genetic testing, autoimmune diseases, allergy diagnostics, drug monitoring & testing and other applications. The infectious diseases segment experience highest market share of IVD reagents market due to rising number of R&D activities and product approvals for infectious disease applications.
“The Asia Pacific region is projected to witness highest growth rate in the IVD reagents market during the forecast period”
The global IVD reagents market is segmented into six regions – North America, Europe, Asia Pacific, the Middle East & Africa, Latin America, and the GCC Countries. Over the span of the forecast period, the IVD reagents market is expected to grow at the fastest rate in the Asia Pacific region. Over the projected period, the Asia Pacific market is expected to develop at the greatest rate due to factors such increasing healthcare spending and an extensive population base.
The primary interviews conducted for this report can be categorized as follows:
- By Company Type: Tier 1 – 42%, Tier 2 – 30%, and Tier 3 – 28%
- By Designation: C-level – 46%, Director-level – 23%, and Others – 31%
- By Region: North America – 23%, Europe – 44%, Asia Pacific – 28%, Latin America – 3%, Middle East & Africa – 1%, and the GCC Countries – 1%
Lists of Companies Profiled in the Report:
Danaher Corporation (US), F. Hoffmann-La Roche Ltd (Switzerland), Abbott (US), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), BioMerieux (France), BD (US), Hologic, Inc. (US), Bio-Rad Laboratories, Inc. (US), Sysmex Corporation (Japan), QIAGEN N.V. (Netherlands), Agilent Technologies, Inc. (US), Revvity (US), DiaSorin S.p.A (Italy), Grifols, S.A. (Spain), Werfen, S.A. (Spain), QuidelOrtho Corporation (US), Chembio Diagnostics, Inc. (US), Surmodics, Inc. (US), Merck KGaA (Germany), MEDICAL & BIOLOGICAL LABORATORIES CO., LTD. (Tokyo), Canvax (Spain), Prestige Diagnostics (US), Adaltis S.r.l. (Italy), and Randox Laboratories Ltd. (UK)
Study Coverage:
In this report, the IVD reagents market has been categorized based on type (antibodies, antigen, purified proteins, and peptides, oligonucleotides, nucleic acid probes, and other IVD reagents), technology (immunoassays, clinical chemistry, molecular diagnostics, hematology, microbiology, coagulation & hemostasis, urinalysis, chromatography & mass spectrometry, immunohistochemistry), application (infectious diseases, oncological applications, endocrinological application, cardiology application, blood screening, genetic testing, autoimmune diseases, allergy diagnostics, drug monitoring & testing, and other applications), test type (laboratory test, and point-of-care tests), end user (hospitals & clinics, clinical laboratories, blood banks, home care settings, pharmaceutical & biotechnology companies, academic institutes, and other end users), and region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa, and the GCC Countries).
Information regarding the main drivers, restraints, opportunities, and challenges influencing the IVD reagents market’s expansion is includes detail in this study. An intensive study of the key players in the IVD reagents market has been done to provide insights into their business profile, service offered, note worthy strategies, acquisitions and expansions, and other deals made pertaining to the market. This study examines the fragmented landscape of emerging IVD reagents startups.
Reasons to buy this report:
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall IVD reagents marketand the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, challenges, opportunities, and restaints.
The report provides insights on the following pointers:
- Analysis of key drivers: (growing geriatric population, gradual shift towards point-of-care testing and automated analyzers, rise in early diagnosis and personalized medicine, increasing adoption of third-party quality controls, growing biotechnology and biopharmaceutical industries, increasing funding for R&D activities), restraints (unfavorable reimbursement scenario, stringent regulatory requirements), opportunities (increasing development of biomarkers, rising significance of companion diagnostics, market growth opportunities in emerging economies, and growing trend of digitalization), and challenges (operational challenges in clinical process) influencing the growth of the in IVD reagents market.
- Market Development: Comprehensive information about lucrative markets – the report analyses the IVD reagents market across varied regions.
- Market Diversification: Exhaustive information about untapped geographies, and investments in the IVD reagents market
- Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players like include F. Hoffmann-La Roche Ltd (Switzerland), Abbott (US), Danaher Corporation (US), Siemens Healthineers AG (Germany), and Thermo Fisher Scientific Inc. (US) are among others, in the IVD reagents market strategies.
Table of Contents
1 INTRODUCTION 38
1.1 STUDY OBJECTIVES 38
1.2 MARKET DEFINITION 38
1.3 STUDY SCOPE 39
1.3.1 MARKETS COVERED AND REGIONAL SCOPE 39
1.3.2 INCLUSIONS AND EXCLUSIONS 40
1.3.3 YEARS CONSIDERED 41
1.4 CURRENCY CONSIDERED 41
1.5 STAKEHOLDERS 41
1.6 MARKET RECONCILIATION 41
2 RESEARCH METHODOLOGY 42
2.1 RESEARCH DATA 42
2.1.1 SECONDARY DATA 43
2.1.1.1 Key data from secondary sources 44
2.1.2 PRIMARY DATA 44
2.1.2.1 Primary sources 45
2.1.2.2 Key industry insights 46
2.1.2.3 Key data from primary sources 46
2.1.2.4 Breakdown of primary interviews 47
2.2 MARKET SIZE ESTIMATION 48
2.2.1 BOTTOM-UP APPROACH 48
2.2.1.1 Approach 1: Company revenue estimation approach 48
2.2.1.2 Approach 2: Presentations of companies and primary interviews 49
2.2.1.3 Approach 3: Primary interviews 49
2.2.1.4 Growth forecast 49
2.2.1.5 CAGR projections 49
2.2.2 TOP-DOWN APPROACH 50
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 51
2.4 RESEARCH ASSUMPTIONS 52
2.4.1 STUDY-RELATED ASSUMPTIONS 52
2.4.2 PARAMETRIC ASSUMPTIONS 52
2.5 RESEARCH LIMITATIONS 53
2.6 RISK ASSESSMENT 53
3 EXECUTIVE SUMMARY 54
4 PREMIUM INSIGHTS 59
4.1 IVD REAGENTS MARKET OVERVIEW 59
4.2 ASIA PACIFIC: IVD REAGENTS MARKET, BY COUNTRY 60
4.3 NORTH AMERICA: IVD REAGENTS MARKET, BY TEST TYPE AND COUNTRY 60
4.4 IVD REAGENTS MARKET, BY COUNTRY 61
5 MARKET OVERVIEW 62
5.1 INTRODUCTION 62
5.2 MARKET DYNAMICS 62
5.2.1 DRIVERS 63
5.2.1.1 Growing geriatric population 63
5.2.1.2 Gradual shift toward point-of-care testing and automated analyzers 64
5.2.1.3 Rise in early diagnosis and personalized medicine 65
5.2.1.4 Increasing adoption of third-party quality controls 66
5.2.1.5 Growing biotechnology and biopharmaceutical industries 67
5.2.1.6 Increasing funding for R&D activities 67
5.2.2 RESTRAINTS 68
5.2.2.1 Unfavorable reimbursement scenario 68
5.2.2.2 Stringent regulatory requirements 68
5.2.3 OPPORTUNITIES 69
5.2.3.1 Increasing development of biomarkers 69
5.2.3.2 Rising significance of companion diagnostics 70
5.2.3.3 Market growth opportunities in emerging economies 71
5.2.3.4 Growing trend of digitalization 72
5.2.4 CHALLENGES 73
5.2.4.1 Operational challenges in clinical process 73
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 74
5.4 PRICING ANALYSIS 75
5.4.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY APPLICATION 75
5.4.2 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY REGION 76
5.4.3 AVERAGE SELLING PRICE TREND, BY TECHNOLOGY 77
5.5 VALUE CHAIN ANALYSIS 77
5.6 SUPPLY CHAIN ANALYSIS 79
5.7 ECOSYSTEM ANALYSIS 80
5.8 INVESTMENT AND FUNDING SCENARIO 81
5.9 TECHNOLOGY ANALYSIS 81
5.9.1 KEY TECHNOLOGIES 82
5.9.2 ADJACENT TECHNOLOGIES 83
5.9.2.1 Multiplexed point-of-care testing 83
5.9.2.2 Nucleic acid lateral flow immunoassay 83
5.9.2.3 DNA-based detection 83
5.9.2.4 Immunodiagnostics 83
5.9.2.5 Dual path technology 83
5.10 PATENT ANALYSIS 84
5.11 TRADE ANALYSIS 85
5.11.1 IMPORT DATA 85
5.11.2 EXPORT DATA 85
5.12 KEY CONFERENCES AND EVENTS, 2024−2025 86
5.13 PORTER’S FIVE FORCES ANALYSIS 86
5.13.1 THREAT OF NEW ENTRANTS 87
5.13.2 THREAT OF SUBSTITUTES 87
5.13.3 BARGAINING POWER OF SUPPLIERS 88
5.13.4 BARGAINING POWER OF BUYERS 88
5.13.5 INTENSITY OF COMPETITIVE RIVALRY 88
5.14 REGULATORY ANALYSIS 88
5.14.1 REGULATORY LANDSCAPE 88
5.14.1.1 North America 89
5.14.1.1.1 US 89
5.14.1.1.2 Canada 90
5.14.1.2 Europe 90
5.14.1.3 Asia Pacific 92
5.14.1.3.1 China 92
5.14.1.3.2 Japan 92
5.14.1.3.3 India 93
5.14.1.4 Latin America 93
5.14.1.4.1 Brazil 93
5.14.1.5 Middle East 94
5.14.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 94
5.14.2.1 North America 94
5.14.2.2 Europe 95
5.14.2.3 Asia Pacific 95
5.14.2.4 Latin America 96
5.14.2.5 Middle East & Africa 96
5.14.2.6 GCC Countries 96
5.15 KEY STAKEHOLDERS AND BUYING CRITERIA 97
5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS 97
5.15.2 BUYING CRITERIA 98
5.16 IMPACT OF AI/GENERATIVE AI ON IVD REAGENTS MARKET 98
5.16.1 INTRODUCTION 98
5.16.2 MARKET POTENTIAL FOR IVD REAGENTS 98
5.16.3 AI USE CASES 99
5.16.4 KEY COMPANIES IMPLEMENTING AI 100
5.16.5 FUTURE OF GENERATIVE AI ON IVD REAGENTS 100
6 IVD REAGENTS MARKET, BY TYPE 101
6.1 INTRODUCTION 102
6.2 ANTIBODIES 102
6.2.1 MONOCLONAL ANTIBODIES 105
6.2.1.1 Increasing incidence of cancer to stimulate growth 105
6.2.2 POLYCLONAL ANTIBODIES 107
6.2.2.1 Rising prevalence of infectious diseases and autoimmune disorders
to support growth 107
6.3 ANTIGENS, PURIFIED PROTEINS, AND PEPTIDES 110
6.3.1 INCREASING FOCUS ON ADVANCED PRECISION MEDICINE
TO ENCOURAGE GROWTH 110
6.4 OLIGONUCLEOTIDES 113
6.4.1 GROWING INCLINATION TOWARD MOLECULAR DIAGNOSTICS TO DRIVE MARKET 113
6.5 NUCLEIC ACID PROBES 116
6.5.1 NEED FOR EARLY DISEASE DETECTION AND MONITORING LOW-ABUNDANCE BIOMARKERS TO AID GROWTH 116
6.6 OTHER IVD REAGENTS 119
7 IVD REAGENTS MARKET, BY TECHNOLOGY 123
7.1 INTRODUCTION 124
7.2 IMMUNOASSAYS 124
7.2.1 RISING TREND OF AUTOMATION TO PROMOTE GROWTH 124
7.3 CLINICAL CHEMISTRY 128
7.3.1 RISING PREVALENCE OF DIABETES TO BOOST SEGMENT 128
7.4 MOLECULAR DIAGNOSTICS 131
7.4.1 GROWING DEMAND FOR BLOOD SCREENING AND POINT-OF-CARE TESTING
TO FUEL MARKET 131
7.5 HEMATOLOGY 133
7.5.1 INCREASING FOCUS ON STEM CELL RESEARCH TO SPEED UP GROWTH 133
7.6 MICROBIOLOGY 136
7.6.1 RISING PREVALENCE OF MICROBIAL INFECTIONS TO FUEL MARKET 136
7.7 COAGULATION & HEMOSTASIS 138
7.7.1 GROWING USE OF ANTICOAGULATION THERAPY TO PROPEL MARKET 138
7.8 URINALYSIS 141
7.8.1 RISING PREVALENCE OF KIDNEY DISEASES TO SUPPORT MARKET GROWTH 141
7.9 CHROMATOGRAPHY & MASS SPECTROMETRY 144
7.9.1 INCREASING APPLICATIONS IN DISEASE SCREENING, FORENSIC ANALYSIS,
AND DRUG THERAPY TO BOOST MARKET 144
7.10 IMMUNOHISTOCHEMISTRY 146
7.10.1 GROWING NUMBER OF LABORATORY TESTS FOR CANCER DIAGNOSIS
TO DRIVE MARKET 146
8 IVD REAGENTS MARKET, BY APPLICATION 150
8.1 INTRODUCTION 151
8.2 INFECTIOUS DISEASES 151
8.2.1 INCREASING PRODUCT LAUNCHES AND APPROVALS TO BOOST MARKET 151
8.3 ONCOLOGICAL APPLICATIONS 154
8.3.1 GROWING EMPHASIS ON EARLY DIAGNOSIS AND QUALITY TREATMENT
TO FUEL MARKET 154
8.4 ENDOCRINOLOGICAL APPLICATIONS 157
8.4.1 RISING PREVALENCE OF DIABETES AND THYROID-RELATED DISORDERS
TO SUSTAIN GROWTH 157
8.5 CARDIOLOGICAL APPLICATIONS 160
8.5.1 CHANGING LIFESTYLES IN DEVELOPED AND DEVELOPING COUNTRIES
TO PROPEL MARKET 160
8.6 BLOOD SCREENING 163
8.6.1 RISING ADOPTION OF AUTOMATED DIAGNOSTIC INSTRUMENTS
TO FACILITATE GROWTH 163
8.7 GENETIC TESTING 166
8.7.1 INCREASING ADOPTION OF GENETIC TESTING TO DIAGNOSE RARE
AND FATAL DISEASES TO SUSTAIN GROWTH 166
8.8 AUTOIMMUNE DISEASES 169
8.8.1 GROWING ADVANCEMENTS IN LABORATORY TECHNOLOGY, REAGENTS,
AND ALTERNATIVE ASSAY METHODOLOGIES TO DRIVE MARKET 169
8.9 ALLERGY DIAGNOSTICS 172
8.9.1 GROWING FOCUS ON ALLERGY THERAPY AND PREVENTION
TO ACCELERATE GROWTH 172
8.10 DRUG MONITORING & TESTING 175
8.10.1 GROWING IMPLEMENTATION OF DRUGS-OF-ABUSE TESTING TO DRIVE MARKET 175
8.11 OTHER APPLICATIONS 178
9 IVD REAGENTS MARKET, BY TEST TYPE 182
9.1 INTRODUCTION 183
9.2 LABORATORY TESTS 183
9.2.1 INCREASING NEED FOR AUTOMATION TO EXPEDITE GROWTH 183
9.3 POINT-OF-CARE TESTS 186
9.3.1 NEED TO CLOSELY MONITOR PATIENT CONDITIONS TO AUGMENT GROWTH 186
10 IVD REAGENTS MARKET, BY END USER 190
10.1 INTRODUCTION 191
10.2 HOSPITALS & CLINICS 191
10.2.1 INCREASING SPECIALTY DIAGNOSTIC TESTS TO ACCELERATE GROWTH 191
10.3 CLINICAL LABORATORIES 194
10.3.1 LARGE REFERENCE LABORATORIES 198
10.3.1.1 Need for specialized testing capabilities and minimal turnaround
time to boost market 198
10.3.2 SMALL & MEDIUM-SIZED LABORATORIES 201
10.3.2.1 Growing adoption of automated and semi-automated instruments
to support growth 201
10.4 BLOOD BANKS 203
10.4.1 GROWING NUMBER OF TRAUMA CASES AND AVAILABILITY OF SOPHISTICATED SURGICAL PROCEDURES TO FUEL MARKET 203
10.5 HOME CARE SETTINGS 206
10.5.1 GROWING PREFERENCE FOR AT-HOME TESTING KITS TO DRIVE MARKET 206
10.6 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 209
10.6.1 INCREASING RESEARCH & DEVELOPMENT EFFORTS TO CONTRIBUTE
TO GROWTH 209
10.7 ACADEMIC INSTITUTES 212
10.7.1 INCREASING INDUSTRY-ACADEMIA COLLABORATIONS TO FAVOR GROWTH 212
10.8 OTHER END USERS 216
11 IVD REAGENTS MARKET, BY REGION 219
11.1 INTRODUCTION 220
11.2 NORTH AMERICA 220
11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 221
11.2.2 US 226
11.2.2.1 Established reimbursement framework to drive market 226
11.2.3 CANADA 230
11.2.3.1 Rising incidence of chronic and infectious lifestyle diseases
to propel market 230
11.3 EUROPE 235
11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 236
11.3.2 GERMANY 240
11.3.2.1 Increasing investments in clinical diagnostics research to drive market 240
11.3.3 UK 244
11.3.3.1 Rising adoption of genome-based testing to promote growth 244
11.3.4 FRANCE 248
11.3.4.1 High healthcare expenditure and rising investments in genomic
medicine to boost market 248
11.3.5 ITALY 251
11.3.5.1 Growing geriatric population and subsequent rise in chronic
conditions to support market growth 251
11.3.6 SPAIN 255
11.3.6.1 Rising adoption of immunoassay reagents to drive market 255
11.3.7 REST OF EUROPE 258
11.4 ASIA PACIFIC 263
11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 263
11.4.2 JAPAN 268
11.4.2.1 Rise in social health insurance programs to encourage growth 268
11.4.3 CHINA 272
11.4.3.1 Growing focus on preventive care to boost demand 272
11.4.4 INDIA 276
11.4.4.1 Rising prevalence of chronic diseases to fuel market 276
11.4.5 REST OF ASIA PACIFIC 280
11.5 LATIN AMERICA 284
11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 284
11.5.2 BRAZIL 288
11.5.2.1 Rising prevalence of diabetes to stimulate growth 288
11.5.3 MEXICO 291
11.5.3.1 Growing establishment of clinical laboratories to boost market 291
11.5.4 REST OF LATIN AMERICA 295
11.6 MIDDLE EAST & AFRICA 298
11.6.1 GROWING FOCUS ON IMMUNOLOGY AND PRENATAL & CANCER TESTING
TO DRIVE MARKET 298
11.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 299
11.7 GCC COUNTRIES 303
11.7.1 MACROECONOMIC OUTLOOK FOR GCC COUNTRIES 303
11.7.2 KINGDOM OF SAUDI ARABIA 307
11.7.2.1 Rising healthcare expenditure to promote growth 307
11.7.3 UNITED ARAB EMIRATES 310
11.7.3.1 Increasing development of advanced healthcare infrastructure
to expedite growth 310
11.7.4 OTHER GCC COUNTRIES 314
12 COMPETITIVE LANDSCAPE 318
12.1 OVERVIEW 318
12.2 KEY PLAYER STRATEGY/RIGHT TO WIN, 2023 318
12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN IVD REAGENTS
MARKET, 2021–2023 318
12.3 REVENUE ANALYSIS, 2021−2023 319
12.4 MARKET SHARE ANALYSIS, 2023 320
12.5 COMPANY VALUATION AND FINANCIAL METRICS 322
12.6 BRAND/PRODUCT COMPARISON 324
12.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 325
12.7.1 STARS 325
12.7.2 EMERGING LEADERS 325
12.7.3 PERVASIVE PLAYERS 325
12.7.4 PARTICIPANTS 325
12.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 327
12.7.5.1 Company footprint 327
12.7.5.2 Technology footprint 328
12.7.5.3 Application footprint 329
12.7.5.4 Test type footprint 330
12.7.5.5 Region footprint 331
12.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 332
12.8.1 PROGRESSIVE COMPANIES 332
12.8.2 RESPONSIVE COMPANIES 332
12.8.3 DYNAMIC COMPANIES 332
12.8.4 STARTING BLOCKS 332
12.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 334
12.8.5.1 Detailed list of key startups/SMEs 334
12.8.5.2 Competitive benchmarking of key startups/SMEs 334
12.9 COMPETITIVE SCENARIO 335
12.9.1 PRODUCT LAUNCHES AND APPROVALS 335
12.9.2 DEALS 336
12.9.3 EXPANSIONS 337
12.9.4 OTHER DEVELOPMENTS 337
13 COMPANY PROFILES 338
13.1 KEY PLAYERS 338
13.1.1 DANAHER CORPORATION 338
13.1.1.1 Business overview 338
13.1.1.2 Products offered 339
13.1.1.3 Recent developments 340
13.1.1.3.1 Deals 340
13.1.1.3.2 Expansions 340
13.1.1.3.3 Other developments 340
13.1.1.4 MnM view 341
13.1.1.4.1 Right to win 341
13.1.1.4.2 Strategic choices 341
13.1.1.4.3 Weaknesses and competitive threats 341
13.1.2 F. HOFFMANN-LA ROCHE LTD. 342
13.1.2.1 Business overview 342
13.1.2.2 Products offered 343
13.1.2.3 Recent developments 344
13.1.2.3.1 Deals 344
13.1.2.4 MnM view 345
13.1.2.4.1 Right to win 345
13.1.2.4.2 Strategic choices 345
13.1.2.4.3 Weaknesses and competitive threats 345
13.1.3 ABBOTT 346
13.1.3.1 Business overview 346
13.1.3.2 Products offered 347
13.1.3.3 Recent developments 348
13.1.3.3.1 Deals 348
13.1.3.4 MnM view 349
13.1.3.4.1 Right to win 349
13.1.3.4.2 Strategic choices 349
13.1.3.4.3 Weaknesses and competitive threats 349
13.1.4 SIEMENS HEALTHINEERS AG 350
13.1.4.1 Business overview 350
13.1.4.2 Products offered 351
13.1.4.3 Recent developments 352
13.1.4.3.1 Deals 352
13.1.4.4 MnM view 353
13.1.4.4.1 Right to win 353
13.1.4.4.2 Strategic choices 353
13.1.4.4.3 Weaknesses and competitive threats 353
13.1.5 THERMO FISHER SCIENTIFIC INC. 354
13.1.5.1 Business overview 354
13.1.5.2 Products offered 355
13.1.5.3 Recent developments 356
13.1.5.3.1 Deals 356
13.1.5.3.2 Expansions 357
13.1.5.4 MnM view 358
13.1.5.4.1 Right to win 358
13.1.5.4.2 Strategic choices 358
13.1.5.4.3 Weaknesses and competitive threats 358
13.1.6 ILLUMINA, INC. 359
13.1.6.1 Business overview 359
13.1.6.2 Products offered 360
13.1.6.3 Recent developments 361
13.1.6.3.1 Deals 361
13.1.7 BIOMÉRIEUX 362
13.1.7.1 Business overview 362
13.1.7.2 Products offered 363
13.1.7.3 Recent developments 364
13.1.7.3.1 Deals 364
13.1.8 BD 365
13.1.8.1 Business overview 365
13.1.8.2 Products offered 367
13.1.8.3 Recent developments 367
13.1.8.3.1 Deals 367
13.1.9 HOLOGIC, INC. 368
13.1.9.1 Business overview 368
13.1.9.2 Products offered 370
13.1.9.3 Recent developments 371
13.1.9.3.1 Product launches and approvals 371
13.1.9.3.2 Deals 371
13.1.10 BIO-RAD LABORATORIES, INC. 372
13.1.10.1 Business overview 372
13.1.10.2 Products offered 374
13.1.10.3 Recent developments 374
13.1.10.3.1 Deals 374
13.1.11 SYSMEX CORPORATION 375
13.1.11.1 Business overview 375
13.1.11.2 Products offered 376
13.1.11.3 Recent developments 377
13.1.11.3.1 Product launches and approvals 377
13.1.11.3.2 Deals 377
13.1.11.3.3 Expansions 377
13.1.12 QIAGEN N.V. 378
13.1.12.1 Business overview 378
13.1.12.2 Products offered 379
13.1.12.3 Recent developments 380
13.1.12.3.1 Deals 380
13.1.13 AGILENT TECHNOLOGIES, INC. 381
13.1.13.1 Business overview 381
13.1.13.2 Products offered 383
13.1.13.3 Recent developments 384
13.1.13.3.1 Deals 384
13.1.13.3.2 Expansions 384
13.1.14 REVVITY 385
13.1.14.1 Business overview 385
13.1.14.2 Products offered 386
13.1.14.3 Recent developments 387
13.1.14.3.1 Deals 387
13.1.14.3.2 Other developments 387
13.1.15 DIASORIN S.P.A. 388
13.1.15.1 Business overview 388
13.1.15.2 Products offered 389
13.1.15.3 Recent developments 391
13.1.15.3.1 Deals 391
13.1.16 GRIFOLS, S.A. 392
13.1.16.1 Business overview 392
13.1.16.2 Products offered 393
13.1.16.3 Recent developments 394
13.1.16.3.1 Deals 394
13.1.17 WERFEN, S.A. 395
13.1.17.1 Business overview 395
13.1.17.2 Products offered 396
13.1.17.3 Recent developments 397
13.1.17.3.1 Deals 397
13.1.18 QUIDELORTHO CORPORATION 398
13.1.18.1 Business overview 398
13.1.18.2 Products offered 400
13.1.18.3 Recent developments 401
13.1.18.3.1 Deals 401
13.1.18.3.2 Expansions 401
13.1.19 CHEMBIO DIAGNOSTICS, INC. 402
13.1.19.1 Business overview 402
13.1.19.2 Products offered 403
13.1.20 SURMODICS, INC. 404
13.1.20.1 Business overview 404
13.1.20.2 Products offered 406
13.1.21 MERCK KGAA 407
13.1.21.1 Business overview 407
13.1.21.2 Products offered 408
13.2 OTHER PLAYERS 410
13.2.1 MEDICAL & BIOLOGICAL LABORATORIES CO., LTD. 410
13.2.2 CANVAX 411
13.2.3 PRESTIGE DIAGNOSTICS 412
13.2.4 ADALTIS S.R.L. 413
13.2.5 RANDOX LABORATORIES LTD. 414
14 APPENDIX 415
14.1 DISCUSSION GUIDE 415
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 420
14.3 CUSTOMIZATION OPTIONS 422
14.4 RELATED REPORTS 422
14.5 AUTHOR DETAILS 423
LIST OF TABLES
TABLE 1 IVD REAGENTS MARKET: INCLUSIONS AND EXCLUSIONS 40
TABLE 2 IVD REAGENTS MARKET: RISK ASSESSMENT 53
TABLE 3 ESTIMATED INCREASE IN GERIATRIC POPULATION, BY REGION, 2022 VS. 2030 VS. 2050 63
TABLE 4 RECENT DEVELOPMENTS IN IVD REAGENTS MARKET IN EMERGING ECONOMIES,
2022–2023 72
TABLE 5 AVERAGE SELLING PRICE TREND OF KEY PLAYERS FOR TOP 2 APPLICATIONS,
2021–2023 (USD) 75
TABLE 6 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY REGION, 2021–2023 (USD) 76
TABLE 7 AVERAGE SELLING PRICE TREND, BY TECHNOLOGY, 2021–2023 (USD) 77
TABLE 8 IVD REAGENTS MARKET: ROLE OF COMPANIES IN ECOSYSTEM 80
TABLE 9 IVD REAGENTS MARKET: KEY TECHNOLOGIES 82
TABLE 10 IMPORT DATA FOR HS CODE 382200, BY COUNTRY, 2019–2023 (USD MILLION) 85
TABLE 11 EXPORT DATA FOR HS CODE 382200, BY COUNTRY, 2019–2023 (USD MILLION) 85
TABLE 12 IVD REAGENTS MARKET: KEY CONFERENCES AND EVENTS, 2024−2025 86
TABLE 13 IVD REAGENTS MARKET: PORTER’S FIVE FORCES ANALYSIS 86
TABLE 14 US: CLASSIFICATION OF QUALITY CONTROL MATERIAL FOR IVD REAGENTS 89
TABLE 15 US: TIME, COST, AND COMPLEXITY OF REGISTRATION FOR IVD REAGENTS 89
TABLE 16 CANADA: CLASSIFICATION OF IVD PRODUCTS 90
TABLE 17 CANADA: TIME, COST, AND COMPLEXITY OF REGISTRATION FOR IVD REAGENTS 90
TABLE 18 EUROPE: ACCREDITATION BODIES FOR MEDICAL LABORATORIES 91
TABLE 19 EUROPE: CLASSIFICATION OF IVD REAGENTS 91
TABLE 20 EUROPE: TIME, COST, AND COMPLEXITY OF REGISTRATION FOR IVD REAGENTS 92
TABLE 21 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION FOR IVD REAGENTS 92
TABLE 22 JAPAN: CLASSIFICATION OF IVD REAGENTS 93
TABLE 23 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION FOR IVD REAGENTS 93
TABLE 24 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 94
TABLE 25 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 95
TABLE 26 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 95
TABLE 27 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 96
TABLE 28 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 96
TABLE 29 GCC COUNTRIES: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 96
TABLE 30 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF IVD REAGENTS,
BY END USER (%) 97
TABLE 31 KEY BUYING CRITERIA FOR IVD REAGENTS, BY END USER 98
TABLE 32 IVD REAGENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 102
TABLE 33 COMPANIES PROVIDING ANTIBODIES 102
TABLE 34 ANTIBODIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 103
TABLE 35 ANTIBODIES MARKET, BY REGION, 2022–2029 (USD MILLION) 103
TABLE 36 NORTH AMERICA: ANTIBODIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 103
TABLE 37 EUROPE: ANTIBODIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 104
TABLE 38 ASIA PACIFIC: ANTIBODIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 104
TABLE 39 LATIN AMERICA: ANTIBODIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 104
TABLE 40 GCC COUNTRIES: ANTIBODIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 105
TABLE 41 MONOCLONAL ANTIBODIES MARKET, BY REGION, 2022–2029 (USD MILLION) 105
TABLE 42 NORTH AMERICA: MONOCLONAL ANTIBODIES MARKET,
BY COUNTRY, 2022–2029 (USD MILLION) 106
TABLE 43 EUROPE: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 106
TABLE 44 ASIA PACIFIC: MONOCLONAL ANTIBODIES MARKET,
BY COUNTRY, 2022–2029 (USD MILLION) 106
TABLE 45 LATIN AMERICA: MONOCLONAL ANTIBODIES MARKET,
BY COUNTRY, 2022–2029 (USD MILLION) 107
TABLE 46 GCC COUNTRIES: MONOCLONAL ANTIBODIES MARKET,
BY COUNTRY, 2022–2029 (USD MILLION) 107
TABLE 47 POLYCLONAL ANTIBODIES MARKET, BY REGION, 2022–2029 (USD MILLION) 108
TABLE 48 NORTH AMERICA: POLYCLONAL ANTIBODIES MARKET,
BY COUNTRY, 2022–2029 (USD MILLION) 108
TABLE 49 EUROPE: POLYCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 109
TABLE 50 ASIA PACIFIC: POLYCLONAL ANTIBODIES MARKET,
BY COUNTRY, 2022–2029 (USD MILLION) 109
TABLE 51 LATIN AMERICA: POLYCLONAL ANTIBODIES MARKET,
BY COUNTRY, 2022–2029 (USD MILLION) 109
TABLE 52 GCC COUNTRIES: POLYCLONAL ANTIBODIES MARKET,
BY COUNTRY, 2022–2029 (USD MILLION) 110
TABLE 53 COMPANIES PROVIDING ANTIGENS, PURIFIED PROTEINS, AND PEPTIDES 110
TABLE 54 ANTIGENS, PURIFIED PROTEINS, AND PEPTIDES MARKET,
BY REGION, 2022–2029 (USD MILLION) 111
TABLE 55 NORTH AMERICA: ANTIGENS, PURIFIED PROTEINS, AND PEPTIDES MARKET,
BY COUNTRY, 2022–2029 (USD MILLION) 111
TABLE 56 EUROPE: ANTIGENS, PURIFIED PROTEINS, AND PEPTIDES MARKET,
BY COUNTRY, 2022–2029 (USD MILLION) 112
TABLE 57 ASIA PACIFIC: ANTIGENS, PURIFIED PROTEINS, AND PEPTIDES MARKET,
BY COUNTRY, 2022–2029 (USD MILLION) 112
TABLE 58 LATIN AMERICA: ANTIGENS, PURIFIED PROTEINS, AND PEPTIDES MARKET,
BY COUNTRY, 2022–2029 (USD MILLION) 113
TABLE 59 GCC COUNTRIES: ANTIGENS, PURIFIED PROTEINS, AND PEPTIDES MARKET,
BY COUNTRY, 2022–2029 (USD MILLION) 113
TABLE 60 COMPANIES PROVIDING OLIGONUCLEOTIDES 114
TABLE 61 OLIGONUCLEOTIDES MARKET, BY REGION, 2022–2029 (USD MILLION) 114
TABLE 62 NORTH AMERICA: OLIGONUCLEOTIDES MARKET,
BY COUNTRY, 2022–2029 (USD MILLION) 115
TABLE 63 EUROPE: OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 115
TABLE 64 ASIA PACIFIC: OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 115
TABLE 65 LATIN AMERICA: OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 116
TABLE 66 GCC COUNTRIES: OLIGONUCLEOTIDES MARKET,
BY COUNTRY, 2022–2029 (USD MILLION) 116
TABLE 67 COMPANIES PROVIDING NUCLEIC ACID PROBES 117
TABLE 68 NUCLEIC ACID PROBES MARKET, BY REGION, 2022–2029 (USD MILLION) 117
TABLE 69 NORTH AMERICA: NUCLEIC ACID PROBES MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 118
TABLE 70 EUROPE: NUCLEIC ACID PROBES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 118
TABLE 71 ASIA PACIFIC: NUCLEIC ACID PROBES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 118
TABLE 72 LATIN AMERICA: NUCLEIC ACID PROBES MARKET,
BY COUNTRY, 2022–2029 (USD MILLION) 119
TABLE 73 GCC COUNTRIES: NUCLEIC ACID PROBES MARKET,
BY COUNTRY, 2022–2029 (USD MILLION) 119
TABLE 74 COMPANIES PROVIDING OTHER IVD REAGENTS 120
TABLE 75 OTHER IVD REAGENTS MARKET, BY REGION, 2022–2029 (USD MILLION) 120
TABLE 76 NORTH AMERICA: OTHER IVD REAGENTS MARKET,
BY COUNTRY, 2022–2029 (USD MILLION) 121
TABLE 77 EUROPE: OTHER IVD REAGENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 121
TABLE 78 ASIA PACIFIC: OTHER IVD REAGENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 121
TABLE 79 LATIN AMERICA: OTHER IVD REAGENTS MARKET,
BY COUNTRY, 2022–2029 (USD MILLION) 122
TABLE 80 GCC COUNTRIES: OTHER IVD REAGENTS MARKET,
BY COUNTRY, 2022–2029 (USD MILLION) 122
TABLE 81 IVD REAGENTS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 124
TABLE 82 IVD REAGENTS MARKET FOR IMMUNOASSAYS, BY REGION, 2022–2029 (USD MILLION) 125
TABLE 83 NORTH AMERICA: IVD REAGENTS MARKET FOR IMMUNOASSAYS,
BY COUNTRY, 2022–2029 (USD MILLION) 125
TABLE 84 EUROPE: IVD REAGENTS MARKET FOR IMMUNOASSAYS,
BY COUNTRY, 2022–2029 (USD MILLION) 126
TABLE 85 ASIA PACIFIC: IVD REAGENTS MARKET FOR IMMUNOASSAYS,
BY COUNTRY, 2022–2029 (USD MILLION) 126
TABLE 86 LATIN AMERICA: IVD REAGENTS MARKET FOR IMMUNOASSAYS,
BY COUNTRY, 2022–2029 (USD MILLION) 127
TABLE 87 GCC COUNTRIES: IVD REAGENTS MARKET FOR IMMUNOASSAYS,
BY COUNTRY, 2022–2029 (USD MILLION) 127
TABLE 88 IVD REAGENTS MARKET FOR CLINICAL CHEMISTRY,
BY REGION, 2022–2029 (USD MILLION) 128
TABLE 89 NORTH AMERICA: IVD REAGENTS MARKET FOR CLINICAL CHEMISTRY,
BY COUNTRY, 2022–2029 (USD MILLION) 128
TABLE 90 EUROPE: IVD REAGENTS MARKET FOR CLINICAL CHEMISTRY,
BY COUNTRY, 2022–2029 (USD MILLION) 129
TABLE 91 ASIA PACIFIC: IVD REAGENTS MARKET FOR CLINICAL CHEMISTRY,
BY COUNTRY, 2022–2029 (USD MILLION) 129
TABLE 92 LATIN AMERICA: IVD REAGENTS MARKET FOR CLINICAL CHEMISTRY,
BY COUNTRY, 2022–2029 (USD MILLION) 130
TABLE 93 GCC COUNTRIES: IVD REAGENTS MARKET FOR CLINICAL CHEMISTRY,
BY COUNTRY, 2022–2029 (USD MILLION) 130
TABLE 94 IVD REAGENTS MARKET FOR MOLECULAR DIAGNOSTICS,
BY REGION, 2022–2029 (USD MILLION) 131
TABLE 95 NORTH AMERICA: IVD REAGENTS MARKET FOR MOLECULAR DIAGNOSTICS,
BY COUNTRY, 2022–2029 (USD MILLION) 131
TABLE 96 EUROPE: IVD REAGENTS MARKET FOR MOLECULAR DIAGNOSTICS,
BY COUNTRY, 2022–2029 (USD MILLION) 132
TABLE 97 ASIA PACIFIC: IVD REAGENTS MARKET FOR MOLECULAR DIAGNOSTICS,
BY COUNTRY, 2022–2029 (USD MILLION) 132
TABLE 98 LATIN AMERICA: IVD REAGENTS MARKET FOR MOLECULAR DIAGNOSTICS,
BY COUNTRY, 2022–2029 (USD MILLION) 133
TABLE 99 GCC COUNTRIES: IVD REAGENTS MARKET FOR MOLECULAR DIAGNOSTICS,
BY COUNTRY, 2022–2029 (USD MILLION) 133
TABLE 100 IVD REAGENTS MARKET FOR HEMATOLOGY, BY REGION, 2022–2029 (USD MILLION) 134
TABLE 101 NORTH AMERICA: IVD REAGENTS MARKET FOR HEMATOLOGY,
BY COUNTRY, 2022–2029 (USD MILLION) 134
TABLE 102 EUROPE: IVD REAGENTS MARKET FOR HEMATOLOGY,
BY COUNTRY, 2022–2029 (USD MILLION) 134
TABLE 103 ASIA PACIFIC: IVD REAGENTS MARKET FOR HEMATOLOGY,
BY COUNTRY, 2022–2029 (USD MILLION) 135
TABLE 104 LATIN AMERICA: IVD REAGENTS MARKET FOR HEMATOLOGY,
BY COUNTRY, 2022–2029 (USD MILLION) 135
TABLE 105 GCC COUNTRIES: IVD REAGENTS MARKET FOR HEMATOLOGY,
BY COUNTRY, 2022–2029 (USD MILLION) 135
TABLE 106 IVD REAGENTS MARKET FOR MICROBIOLOGY, BY REGION, 2022–2029 (USD MILLION) 136
TABLE 107 NORTH AMERICA: IVD REAGENTS MARKET FOR MICROBIOLOGY,
BY COUNTRY, 2022–2029 (USD MILLION) 137
TABLE 108 EUROPE: IVD REAGENTS MARKET FOR MICROBIOLOGY,
BY COUNTRY, 2022–2029 (USD MILLION) 137
TABLE 109 ASIA PACIFIC: IVD REAGENTS MARKET FOR MICROBIOLOGY,
BY COUNTRY, 2022–2029 (USD MILLION) 137
TABLE 110 LATIN AMERICA: IVD REAGENTS MARKET FOR MICROBIOLOGY,
BY COUNTRY, 2022–2029 (USD MILLION) 138
TABLE 111 GCC COUNTRIES: IVD REAGENTS MARKET FOR MICROBIOLOGY,
BY COUNTRY, 2022–2029 (USD MILLION) 138
TABLE 112 IVD REAGENTS MARKET FOR COAGULATION & HEMOSTASIS,
BY REGION, 2022–2029 (USD MILLION) 139
TABLE 113 NORTH AMERICA: IVD REAGENTS MARKET FOR COAGULATION & HEMOSTASIS,
BY COUNTRY, 2022–2029 (USD MILLION) 139
TABLE 114 EUROPE: IVD REAGENTS MARKET FOR COAGULATION & HEMOSTASIS,
BY COUNTRY, 2022–2029 (USD MILLION) 140
TABLE 115 ASIA PACIFIC: IVD REAGENTS MARKET FOR COAGULATION & HEMOSTASIS,
BY COUNTRY, 2022–2029 (USD MILLION) 140
TABLE 116 LATIN AMERICA: IVD REAGENTS MARKET FOR COAGULATION & HEMOSTASIS,
BY COUNTRY, 2022–2029 (USD MILLION) 141
TABLE 117 GCC COUNTRIES: IVD REAGENTS MARKET FOR COAGULATION & HEMOSTASIS,
BY COUNTRY, 2022–2029 (USD MILLION) 141
TABLE 118 IVD REAGENTS MARKET FOR URINALYSIS, BY REGION, 2022–2029 (USD MILLION) 142
TABLE 119 NORTH AMERICA: IVD REAGENTS MARKET FOR URINALYSIS,
BY COUNTRY, 2022–2029 (USD MILLION) 142
TABLE 120 EUROPE: IVD REAGENTS MARKET FOR URINALYSIS,
BY COUNTRY, 2022–2029 (USD MILLION) 142
TABLE 121 ASIA PACIFIC: IVD REAGENTS MARKET FOR URINALYSIS,
BY COUNTRY, 2022–2029 (USD MILLION) 143
TABLE 122 LATIN AMERICA: IVD REAGENTS MARKET FOR URINALYSIS,
BY COUNTRY, 2022–2029 (USD MILLION) 143
TABLE 123 GCC COUNTRIES: IVD REAGENTS MARKET FOR URINALYSIS,
BY COUNTRY, 2022–2029 (USD MILLION) 143
TABLE 124 IVD REAGENTS MARKET FOR CHROMATOGRAPHY & MASS SPECTROMETRY,
BY REGION, 2022–2029 (USD MILLION) 144
TABLE 125 NORTH AMERICA: IVD REAGENTS MARKET FOR CHROMATOGRAPHY &
MASS SPECTROMETRY, BY COUNTRY, 2022–2029 (USD MILLION) 145
TABLE 126 EUROPE: IVD REAGENTS MARKET FOR CHROMATOGRAPHY & MASS SPECTROMETRY,
BY COUNTRY, 2022–2029 (USD MILLION) 145
TABLE 127 ASIA PACIFIC: IVD REAGENTS MARKET FOR CHROMATOGRAPHY &
MASS SPECTROMETRY, BY COUNTRY, 2022–2029 (USD MILLION) 145
TABLE 128 LATIN AMERICA: IVD REAGENTS MARKET FOR CHROMATOGRAPHY
& MASS SPECTROMETRY, BY COUNTRY, 2022–2029 (USD MILLION) 146
TABLE 129 GCC COUNTRIES: IVD REAGENTS MARKET FOR CHROMATOGRAPHY
& MASS SPECTROMETRY, BY COUNTRY, 2022–2029 (USD MILLION) 146
TABLE 130 IVD REAGENTS MARKET FOR IMMUNOHISTOCHEMISTRY,
BY REGION, 2022–2029 (USD MILLION) 147
TABLE 131 NORTH AMERICA: IVD REAGENTS MARKET FOR IMMUNOHISTOCHEMISTRY,
BY COUNTRY, 2022–2029 (USD MILLION) 147
TABLE 132 EUROPE: IVD REAGENTS MARKET FOR IMMUNOHISTOCHEMISTRY,
BY COUNTRY, 2022–2029 (USD MILLION) 148
TABLE 133 ASIA PACIFIC: IVD REAGENTS MARKET FOR IMMUNOHISTOCHEMISTRY,
BY COUNTRY, 2022–2029 (USD MILLION) 148
TABLE 134 LATIN AMERICA: IVD REAGENTS MARKET FOR IMMUNOHISTOCHEMISTRY,
BY COUNTRY, 2022–2029 (USD MILLION) 149
TABLE 135 GCC COUNTRIES: IVD REAGENTS MARKET FOR IMMUNOHISTOCHEMISTRY,
BY COUNTRY, 2022–2029 (USD MILLION) 149
TABLE 136 IVD REAGENTS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 151
TABLE 137 IVD REAGENTS MARKET FOR INFECTIOUS DISEASES,
BY REGION, 2022–2029 (USD MILLION) 152
TABLE 138 NORTH AMERICA: IVD REAGENTS MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY, 2022–2029 (USD MILLION) 152
TABLE 139 EUROPE: IVD REAGENTS MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY, 2022–2029 (USD MILLION) 153
TABLE 140 ASIA PACIFIC: IVD REAGENTS MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY, 2022–2029 (USD MILLION) 153
TABLE 141 LATIN AMERICA: IVD REAGENTS MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY, 2022–2029 (USD MILLION) 154
TABLE 142 GCC COUNTRIES: IVD REAGENTS MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY, 2022–2029 (USD MILLION) 154
TABLE 143 ESTIMATED NUMBER OF NEW CASES OF CANCER FOR 0–85+ YEARS OF AGE,
2022 VS. 2030 155
TABLE 144 IVD REAGENTS MARKET FOR ONCOLOGICAL APPLICATIONS,
BY REGION, 2022–2029 (USD MILLION) 155
TABLE 145 NORTH AMERICA: IVD REAGENTS MARKET FOR ONCOLOGICAL APPLICATIONS,
BY COUNTRY, 2022–2029 (USD MILLION) 156
TABLE 146 EUROPE: IVD REAGENTS MARKET FOR ONCOLOGICAL APPLICATIONS,
BY COUNTRY, 2022–2029 (USD MILLION) 156
TABLE 147 ASIA PACIFIC: IVD REAGENTS MARKET FOR ONCOLOGICAL APPLICATIONS,
BY COUNTRY, 2022–2029 (USD MILLION) 156
TABLE 148 LATIN AMERICA: IVD REAGENTS MARKET FOR ONCOLOGICAL APPLICATIONS,
BY COUNTRY, 2022–2029 (USD MILLION) 157
TABLE 149 GCC COUNTRIES: IVD REAGENTS MARKET FOR ONCOLOGICAL APPLICATIONS,
BY COUNTRY, 2022–2029 (USD MILLION) 157
TABLE 150 IVD REAGENTS MARKET FOR ENDOCRINOLOGICAL APPLICATIONS,
BY REGION, 2022–2029 (USD MILLION) 158
TABLE 151 NORTH AMERICA: IVD REAGENTS MARKET FOR ENDOCRINOLOGICAL APPLICATIONS,
BY COUNTRY, 2022–2029 (USD MILLION) 158
TABLE 152 EUROPE: IVD REAGENTS MARKET FOR ENDOCRINOLOGICAL APPLICATIONS,
BY COUNTRY, 2022–2029 (USD MILLION) 159
TABLE 153 ASIA PACIFIC: IVD REAGENTS MARKET FOR ENDOCRINOLOGICAL APPLICATIONS,
BY COUNTRY, 2022–2029 (USD MILLION) 159
TABLE 154 LATIN AMERICA: IVD REAGENTS MARKET FOR ENDOCRINOLOGICAL APPLICATIONS,
BY COUNTRY, 2022–2029 (USD MILLION) 160
TABLE 155 GCC COUNTRIES: IVD REAGENTS MARKET FOR ENDOCRINOLOGICAL APPLICATIONS,
BY COUNTRY, 2022–2029 (USD MILLION) 160
TABLE 156 IVD REAGENTS MARKET FOR CARDIOLOGICAL APPLICATIONS,
BY REGION, 2022–2029 (USD MILLION) 161
TABLE 157 NORTH AMERICA: IVD REAGENTS MARKET FOR CARDIOLOGICAL APPLICATIONS,
BY COUNTRY, 2022–2029 (USD MILLION) 161
TABLE 158 EUROPE: IVD REAGENTS MARKET FOR CARDIOLOGICAL APPLICATIONS,
BY COUNTRY, 2022–2029 (USD MILLION) 162
TABLE 159 ASIA PACIFIC: IVD REAGENTS MARKET FOR CARDIOLOGICAL APPLICATIONS,
BY COUNTRY, 2022–2029 (USD MILLION) 162
TABLE 160 LATIN AMERICA: IVD REAGENTS MARKET FOR CARDIOLOGICAL APPLICATIONS,
BY COUNTRY, 2022–2029 (USD MILLION) 163
TABLE 161 GCC COUNTRIES: IVD REAGENTS MARKET FOR CARDIOLOGICAL APPLICATIONS,
BY COUNTRY, 2022–2029 (USD MILLION) 163
TABLE 162 IVD REAGENTS MARKET FOR BLOOD SCREENING,
BY REGION, 2022–2029 (USD MILLION) 164
TABLE 163 NORTH AMERICA: IVD REAGENTS MARKET FOR BLOOD SCREENING,
BY COUNTRY, 2022–2029 (USD MILLION) 164
TABLE 164 EUROPE: IVD REAGENTS MARKET FOR BLOOD SCREENING,
BY COUNTRY, 2022–2029 (USD MILLION) 165
TABLE 165 ASIA PACIFIC: IVD REAGENTS MARKET FOR BLOOD SCREENING,
BY COUNTRY, 2022–2029 (USD MILLION) 165
TABLE 166 LATIN AMERICA: IVD REAGENTS MARKET FOR BLOOD SCREENING,
BY COUNTRY, 2022–2029 (USD MILLION) 166
TABLE 167 GCC COUNTRIES: IVD REAGENTS MARKET FOR BLOOD SCREENING,
BY COUNTRY, 2022–2029 (USD MILLION) 166
TABLE 168 IVD REAGENTS MARKET FOR GENETIC TESTING, BY REGION, 2022–2029 (USD MILLION) 167
TABLE 169 NORTH AMERICA: IVD REAGENTS MARKET FOR GENETIC TESTING,
BY COUNTRY, 2022–2029 (USD MILLION) 167
TABLE 170 EUROPE: IVD REAGENTS MARKET FOR GENETIC TESTING,
BY COUNTRY, 2022–2029 (USD MILLION) 168
TABLE 171 ASIA PACIFIC: IVD REAGENTS MARKET FOR GENETIC TESTING,
BY COUNTRY, 2022–2029 (USD MILLION) 168
TABLE 172 LATIN AMERICA: IVD REAGENTS MARKET FOR GENETIC TESTING,
BY COUNTRY, 2022–2029 (USD MILLION) 169
TABLE 173 GCC COUNTRIES: IVD REAGENTS MARKET FOR GENETIC TESTING,
BY COUNTRY, 2022–2029 (USD MILLION) 169
TABLE 174 IVD REAGENTS MARKET FOR AUTOIMMUNE DISEASES,
BY REGION, 2022–2029 (USD MILLION) 170
TABLE 175 NORTH AMERICA: IVD REAGENTS MARKET FOR AUTOIMMUNE DISEASES,
BY COUNTRY, 2022–2029 (USD MILLION) 171
TABLE 176 EUROPE: IVD REAGENTS MARKET FOR AUTOIMMUNE DISEASES,
BY COUNTRY, 2022–2029 (USD MILLION) 171
TABLE 177 ASIA PACIFIC: IVD REAGENTS MARKET FOR AUTOIMMUNE DISEASES,
BY COUNTRY, 2022–2029 (USD MILLION) 171
TABLE 178 LATIN AMERICA: IVD REAGENTS MARKET FOR AUTOIMMUNE DISEASES,
BY COUNTRY, 2022–2029 (USD MILLION) 172
TABLE 179 GCC COUNTRIES: IVD REAGENTS MARKET FOR AUTOIMMUNE DISEASES,
BY COUNTRY, 2022–2029 (USD MILLION) 172
TABLE 180 IVD REAGENTS MARKET FOR ALLERGY DIAGNOSTICS,
BY REGION, 2022–2029 (USD MILLION) 173
TABLE 181 NORTH AMERICA: IVD REAGENTS MARKET FOR ALLERGY DIAGNOSTICS,
BY COUNTRY, 2022–2029 (USD MILLION) 173
TABLE 182 EUROPE: IVD REAGENTS MARKET FOR ALLERGY DIAGNOSTICS,
BY COUNTRY, 2022–2029 (USD MILLION) 174
TABLE 183 ASIA PACIFIC: IVD REAGENTS MARKET FOR ALLERGY DIAGNOSTICS,
BY COUNTRY, 2022–2029 (USD MILLION) 174
TABLE 184 LATIN AMERICA: IVD REAGENTS MARKET FOR ALLERGY DIAGNOSTICS,
BY COUNTRY, 2022–2029 (USD MILLION) 175
TABLE 185 GCC COUNTRIES: IVD REAGENTS MARKET FOR ALLERGY DIAGNOSTICS,
BY COUNTRY, 2022–2029 (USD MILLION) 175
TABLE 186 KEY PRODUCTS FOR DRUG MONITORING 176
TABLE 187 IVD REAGENTS MARKET FOR DRUG MONITORING & TESTING,
BY REGION, 2022–2029 (USD MILLION) 176
TABLE 188 NORTH AMERICA: IVD REAGENTS MARKET FOR DRUG MONITORING & TESTING,
BY COUNTRY, 2022–2029 (USD MILLION) 177
TABLE 189 EUROPE: IVD REAGENTS MARKET FOR DRUG MONITORING & TESTING,
BY COUNTRY, 2022–2029 (USD MILLION) 177
TABLE 190 ASIA PACIFIC: IVD REAGENTS MARKET FOR DRUG MONITORING & TESTING,
BY COUNTRY, 2022–2029 (USD MILLION) 177
TABLE 191 LATIN AMERICA: IVD REAGENTS MARKET FOR DRUG MONITORING & TESTING,
BY COUNTRY, 2022–2029 (USD MILLION) 178
TABLE 192 GCC COUNTRIES: IVD REAGENTS MARKET FOR DRUG MONITORING & TESTING,
BY COUNTRY, 2022–2029 (USD MILLION) 178
TABLE 193 IVD REAGENTS MARKET FOR OTHER APPLICATIONS,
BY REGION, 2022–2029 (USD MILLION) 179
TABLE 194 NORTH AMERICA: IVD REAGENTS MARKET FOR OTHER APPLICATIONS,
BY COUNTRY, 2022–2029 (USD MILLION) 179
TABLE 195 EUROPE: IVD REAGENTS MARKET FOR OTHER APPLICATIONS,
BY COUNTRY, 2022–2029 (USD MILLION) 180
TABLE 196 ASIA PACIFIC: IVD REAGENTS MARKET FOR OTHER APPLICATIONS,
BY COUNTRY, 2022–2029 (USD MILLION) 180
TABLE 197 LATIN AMERICA: IVD REAGENTS MARKET FOR OTHER APPLICATIONS,
BY COUNTRY, 2022–2029 (USD MILLION) 181
TABLE 198 GCC COUNTRIES: IVD REAGENTS MARKET FOR OTHER APPLICATIONS,
BY COUNTRY, 2022–2029 (USD MILLION) 181
TABLE 199 IVD REAGENTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION) 183
TABLE 200 IVD REAGENTS MARKET FOR LABORATORY TESTS,
BY REGION, 2022–2029 (USD MILLION) 184
TABLE 201 NORTH AMERICA: IVD REAGENTS MARKET FOR LABORATORY TESTS,
BY COUNTRY, 2022–2029 (USD MILLION) 184
TABLE 202 EUROPE: IVD REAGENTS MARKET FOR LABORATORY TESTS,
BY COUNTRY, 2022–2029 (USD MILLION) 185
TABLE 203 ASIA PACIFIC: IVD REAGENTS MARKET FOR LABORATORY TESTS,
BY COUNTRY, 2022–2029 (USD MILLION) 185
TABLE 204 LATIN AMERICA: IVD REAGENTS MARKET FOR LABORATORY TESTS,
BY COUNTRY, 2022–2029 (USD MILLION) 186
TABLE 205 GCC COUNTRIES: IVD REAGENTS MARKET FOR LABORATORY TESTS,
BY COUNTRY, 2022–2029 (USD MILLION) 186
TABLE 206 IVD REAGENTS MARKET FOR POINT-OF-CARE TESTS,
BY REGION, 2022–2029 (USD MILLION) 187
TABLE 207 NORTH AMERICA: IVD REAGENTS MARKET FOR POINT-OF-CARE TESTS,
BY COUNTRY, 2022–2029 (USD MILLION) 187
TABLE 208 EUROPE: IVD REAGENTS MARKET FOR POINT-OF-CARE TESTS,
BY COUNTRY, 2022–2029 (USD MILLION) 188
TABLE 209 ASIA PACIFIC: IVD REAGENTS MARKET FOR POINT-OF-CARE TESTS,
BY COUNTRY, 2022–2029 (USD MILLION) 188
TABLE 210 LATIN AMERICA: IVD REAGENTS MARKET FOR POINT-OF-CARE TESTS,
BY COUNTRY, 2022–2029 (USD MILLION) 189
TABLE 211 GCC COUNTRIES: IVD REAGENTS MARKET FOR POINT-OF-CARE TESTS,
BY COUNTRY, 2022–2029 (USD MILLION) 189
TABLE 212 IVD REAGENTS MARKET, BY END USER, 2022–2029 (USD MILLION) 191
TABLE 213 IVD REAGENTS MARKET FOR HOSPITALS & CLINICS,
BY REGION, 2022–2029 (USD MILLION) 192
TABLE 214 NORTH AMERICA: IVD REAGENTS MARKET FOR HOSPITALS & CLINICS,
BY COUNTRY, 2022–2029 (USD MILLION) 192
TABLE 215 EUROPE: IVD REAGENTS MARKET FOR HOSPITALS & CLINICS,
BY COUNTRY, 2022–2029 (USD MILLION) 193
TABLE 216 ASIA PACIFIC: IVD REAGENTS MARKET FOR HOSPITALS & CLINICS,
BY COUNTRY, 2022–2029 (USD MILLION) 193
TABLE 217 LATIN AMERICA: IVD REAGENTS MARKET FOR HOSPITALS & CLINICS,
BY COUNTRY, 2022–2029 (USD MILLION) 194
TABLE 218 GCC COUNTRIES: IVD REAGENTS MARKET FOR HOSPITALS & CLINICS,
BY COUNTRY, 2022–2029 (USD MILLION) 194
TABLE 219 IVD REAGENTS MARKET FOR CLINICAL LABORATORIES,
BY REGION, 2022–2029 (USD MILLION) 195
TABLE 220 IVD REAGENTS MARKET FOR CLINICAL LABORATORIES,
BY TYPE, 2022–2029 (USD MILLION) 195
TABLE 221 NORTH AMERICA: IVD REAGENTS MARKET FOR CLINICAL LABORATORIES,
BY COUNTRY, 2022–2029 (USD MILLION) 195
TABLE 222 EUROPE: IVD REAGENTS MARKET FOR CLINICAL LABORATORIES,
BY COUNTRY, 2022–2029 (USD MILLION) 196
TABLE 223 ASIA PACIFIC: IVD REAGENTS MARKET FOR CLINICAL LABORATORIES,
BY COUNTRY, 2022–2029 (USD MILLION) 196
TABLE 224 LATIN AMERICA: IVD REAGENTS MARKET FOR CLINICAL LABORATORIES,
BY COUNTRY, 2022–2029 (USD MILLION) 197
TABLE 225 GCC COUNTRIES: IVD REAGENTS MARKET FOR CLINICAL LABORATORIES,
BY COUNTRY, 2022–2029 (USD MILLION) 197
TABLE 226 IVD REAGENTS MARKET FOR LARGE REFERENCE LABORATORIES,
BY REGION, 2022–2029 (USD MILLION) 198
TABLE 227 NORTH AMERICA: IVD REAGENTS MARKET FOR LARGE REFERENCE LABORATORIES,
BY COUNTRY, 2022–2029 (USD MILLION) 198
TABLE 228 EUROPE: IVD REAGENTS MARKET FOR LARGE REFERENCE LABORATORIES,
BY COUNTRY, 2022–2029 (USD MILLION) 199
TABLE 229 ASIA PACIFIC: IVD REAGENTS MARKET FOR LARGE REFERENCE LABORATORIES,
BY COUNTRY, 2022–2029 (USD MILLION) 199
TABLE 230 LATIN AMERICA: IVD REAGENTS MARKET FOR LARGE REFERENCE LABORATORIES,
BY COUNTRY, 2022–2029 (USD MILLION) 200
TABLE 231 GCC COUNTRIES: IVD REAGENTS MARKET FOR LARGE REFERENCE LABORATORIES,
BY COUNTRY, 2022–2029 (USD MILLION) 200
TABLE 232 IVD REAGENTS MARKET FOR SMALL & MEDIUM LABORATORIES,
BY REGION, 2022–2029 (USD MILLION) 201
TABLE 233 NORTH AMERICA: IVD REAGENTS MARKET FOR SMALL & MEDIUM LABORATORIES,
BY COUNTRY, 2022–2029 (USD MILLION) 201
TABLE 234 EUROPE: IVD REAGENTS MARKET FOR SMALL & MEDIUM LABORATORIES,
BY COUNTRY, 2022–2029 (USD MILLION) 202
TABLE 235 ASIA PACIFIC: IVD REAGENTS MARKET FOR SMALL & MEDIUM LABORATORIES,
BY COUNTRY, 2022–2029 (USD MILLION) 202
TABLE 236 LATIN AMERICA: IVD REAGENTS MARKET FOR SMALL & MEDIUM LABORATORIES,
BY COUNTRY, 2022–2029 (USD MILLION) 203
TABLE 237 GCC COUNTRIES: IVD REAGENTS MARKET FOR SMALL & MEDIUM LABORATORIES,
BY COUNTRY, 2022–2029 (USD MILLION) 203
TABLE 238 IVD REAGENTS MARKET FOR BLOOD BANKS, BY REGION, 2022–2029 (USD MILLION) 204
TABLE 239 NORTH AMERICA: IVD REAGENTS MARKET FOR BLOOD BANKS,
BY COUNTRY, 2022–2029 (USD MILLION) 204
TABLE 240 EUROPE: IVD REAGENTS MARKET FOR BLOOD BANKS,
BY COUNTRY, 2022–2029 (USD MILLION) 205
TABLE 241 ASIA PACIFIC: IVD REAGENTS MARKET FOR BLOOD BANKS,
BY COUNTRY, 2022–2029 (USD MILLION) 205
TABLE 242 LATIN AMERICA: IVD REAGENTS MARKET FOR BLOOD BANKS,
BY COUNTRY, 2022–2029 (USD MILLION) 206
TABLE 243 GCC COUNTRIES: IVD REAGENTS MARKET FOR BLOOD BANKS,
BY COUNTRY, 2022–2029 (USD MILLION) 206
TABLE 244 IVD REAGENTS MARKET FOR HOME CARE SETTINGS,
BY REGION, 2022–2029 (USD MILLION) 207
TABLE 245 NORTH AMERICA: IVD REAGENTS MARKET FOR HOME CARE SETTINGS,
BY COUNTRY, 2022–2029 (USD MILLION) 208
TABLE 246 EUROPE: IVD REAGENTS MARKET FOR HOME CARE SETTINGS,
BY COUNTRY, 2022–2029 (USD MILLION) 208
TABLE 247 ASIA PACIFIC: IVD REAGENTS MARKET FOR HOME CARE SETTINGS,
BY COUNTRY, 2022–2029 (USD MILLION) 208
TABLE 248 LATIN AMERICA: IVD REAGENTS MARKET FOR HOME CARE SETTINGS,
BY COUNTRY, 2022–2029 (USD MILLION) 209
TABLE 249 GCC COUNTRIES: IVD REAGENTS MARKET FOR HOME CARE SETTINGS,
BY COUNTRY, 2022–2029 (USD MILLION) 209
TABLE 250 IVD REAGENTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES,
BY REGION, 2022–2029 (USD MILLION) 210
TABLE 251 NORTH AMERICA: IVD REAGENTS MARKET FOR PHARMACEUTICAL &
BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION) 210
TABLE 252 EUROPE: IVD REAGENTS MARKET FOR PHARMACEUTICAL &
BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION) 211
TABLE 253 ASIA PACIFIC: IVD REAGENTS MARKET FOR PHARMACEUTICAL &
BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION) 211
TABLE 254 LATIN AMERICA: IVD REAGENTS MARKET FOR PHARMACEUTICAL &
BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION) 211
TABLE 255 GCC COUNTRIES: IVD REAGENTS MARKET FOR PHARMACEUTICAL &
BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION) 212
TABLE 256 IVD REAGENTS MARKET FOR ACADEMIC INSTITUTES,
BY REGION, 2022–2029 (USD MILLION) 213
TABLE 257 NORTH AMERICA: IVD REAGENTS MARKET FOR ACADEMIC INSTITUTES,
BY COUNTRY, 2022–2029 (USD MILLION) 213
TABLE 258 EUROPE: IVD REAGENTS MARKET FOR ACADEMIC INSTITUTES,
BY COUNTRY, 2022–2029 (USD MILLION) 214
TABLE 259 ASIA PACIFIC: IVD REAGENTS MARKET FOR ACADEMIC INSTITUTES,
BY COUNTRY, 2022–2029 (USD MILLION) 214
TABLE 260 LATIN AMERICA: IVD REAGENTS MARKET FOR ACADEMIC INSTITUTES,
BY COUNTRY, 2022–2029 (USD MILLION) 215
TABLE 261 GCC COUNTRIES: IVD REAGENTS MARKET FOR ACADEMIC INSTITUTES,
BY COUNTRY, 2022–2029 (USD MILLION) 215
TABLE 262 IVD REAGENTS MARKET FOR OTHER END USERS, BY REGION,
2022–2029 (USD MILLION) 216
TABLE 263 NORTH AMERICA: IVD REAGENTS MARKET FOR OTHER END USERS,
BY COUNTRY, 2022–2029 (USD MILLION) 216
TABLE 264 EUROPE: IVD REAGENTS MARKET FOR OTHER END USERS,
BY COUNTRY, 2022–2029 (USD MILLION) 217
TABLE 265 ASIA PACIFIC: IVD REAGENTS MARKET FOR OTHER END USERS,
BY COUNTRY, 2022–2029 (USD MILLION) 217
TABLE 266 LATIN AMERICA: IVD REAGENTS MARKET FOR OTHER END USERS,
BY COUNTRY, 2022–2029 (USD MILLION) 218
TABLE 267 GCC COUNTRIES: IVD REAGENTS MARKET FOR OTHER END USERS,
BY COUNTRY, 2022–2029 (USD MILLION) 218
TABLE 268 IVD REAGENTS MARKET, BY REGION, 2022–2029 (USD MILLION) 220
TABLE 269 KEY IVD REAGENTS PROVIDED BY MAJOR PLAYERS IN NORTH AMERICA 221
TABLE 270 NORTH AMERICA: MACROECONOMIC INDICATORS 221
TABLE 271 NORTH AMERICA: IVD REAGENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 223
TABLE 272 NORTH AMERICA: IVD TESTS CONDUCTED, BY COUNTRY, 2022–2029 (BILLION UNIT) 223
TABLE 273 NORTH AMERICA: IVD REAGENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 223
TABLE 274 NORTH AMERICA: ANTIBODIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 224
TABLE 275 NORTH AMERICA: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 224
TABLE 276 NORTH AMERICA: IVD REAGENTS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 225
TABLE 277 NORTH AMERICA: IVD REAGENTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION) 225
TABLE 278 NORTH AMERICA: IVD REAGENTS MARKET, BY END USER, 2022–2029 (USD MILLION) 226
TABLE 279 NORTH AMERICA: CLINICAL LABORATORIES MARKET,
BY TYPE, 2022–2029 (USD MILLION) 226
TABLE 280 US: IVD REAGENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 227
TABLE 281 US: ANTIBODIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 228
TABLE 282 US: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 228
TABLE 283 US: IVD REAGENTS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 229
TABLE 284 US: IVD REAGENTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION) 229
TABLE 285 US: IVD REAGENTS MARKET, BY END USER, 2022–2029 (USD MILLION) 230
TABLE 286 US: CLINICAL LABORATORIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 230
TABLE 287 CANADA: IVD REAGENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 232
TABLE 288 CANADA: ANTIBODIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 232
TABLE 289 CANADA: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 233
TABLE 290 CANADA: IVD REAGENTS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 233
TABLE 291 CANADA: IVD REAGENTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION) 234
TABLE 292 CANADA: IVD REAGENTS MARKET, BY END USER, 2022–2029 (USD MILLION) 234
TABLE 293 CANADA: CLINICAL LABORATORIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 234
TABLE 294 KEY IVD REAGENTS PROVIDED BY MAJOR PLAYERS IN EUROPE 236
TABLE 295 EUROPE: MACROECONOMIC INDICATORS 236
TABLE 296 EUROPE: IVD REAGENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 237
TABLE 297 EUROPE: IVD REAGENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 237
TABLE 298 EUROPE: ANTIBODIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 237
TABLE 299 EUROPE: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 238
TABLE 300 EUROPE: IVD REAGENTS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 238
TABLE 301 EUROPE: IVD REAGENTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION) 239
TABLE 302 EUROPE: IVD REAGENTS MARKET, BY END USER, 2022–2029 (USD MILLION) 239
TABLE 303 EUROPE: CLINICAL LABORATORIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 239
TABLE 304 GERMANY: IVD REAGENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 241
TABLE 305 GERMANY: ANTIBODIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 241
TABLE 306 GERMANY: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 242
TABLE 307 GERMANY: IVD REAGENTS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 242
TABLE 308 GERMANY: IVD REAGENTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION) 243
TABLE 309 GERMANY: IVD REAGENTS MARKET, BY END USER, 2022–2029 (USD MILLION) 243
TABLE 310 GERMANY: CLINICAL LABORATORIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 243
TABLE 311 UK: IVD REAGENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 245
TABLE 312 UK: ANTIBODIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 245
TABLE 313 UK: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 246
TABLE 314 UK: IVD REAGENTS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 246
TABLE 315 UK: IVD REAGENTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION) 247
TABLE 316 UK: IVD REAGENTS MARKET, BY END USER, 2022–2029 (USD MILLION) 247
TABLE 317 UK: CLINICAL LABORATORIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 247
TABLE 318 FRANCE: IVD REAGENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 248
TABLE 319 FRANCE: ANTIBODIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 249
TABLE 320 FRANCE: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 249
TABLE 321 FRANCE: IVD REAGENTS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 250
TABLE 322 FRANCE: IVD REAGENTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION) 250
TABLE 323 FRANCE: IVD REAGENTS MARKET, BY END USER, 2022–2029 (USD MILLION) 251
TABLE 324 FRANCE: CLINICAL LABORATORIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 251
TABLE 325 ITALY: IVD REAGENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 252
TABLE 326 ITALY: ANTIBODIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 252
TABLE 327 ITALY: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 253
TABLE 328 ITALY: IVD REAGENTS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 253
TABLE 329 ITALY: IVD REAGENTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION) 254
TABLE 330 ITALY: IVD REAGENTS MARKET, BY END USER, 2022–2029 (USD MILLION) 254
TABLE 331 ITALY: CLINICAL LABORATORIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 254
TABLE 332 SPAIN: IVD REAGENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 255
TABLE 333 SPAIN: ANTIBODIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 256
TABLE 334 SPAIN: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 256
TABLE 335 SPAIN: IVD REAGENTS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 257
TABLE 336 SPAIN: IVD REAGENTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION) 257
TABLE 337 SPAIN: IVD REAGENTS MARKET, BY END USER, 2022–2029 (USD MILLION) 258
TABLE 338 SPAIN: CLINICAL LABORATORIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 258
TABLE 339 REST OF EUROPE: IVD REAGENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 259
TABLE 340 REST OF EUROPE: ANTIBODIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 260
TABLE 341 REST OF EUROPE: IVD REAGENTS MARKET, BY TECHNOLOGY,
2022–2029 (USD MILLION) 260
TABLE 342 REST OF EUROPE: IVD REAGENTS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 261
TABLE 343 REST OF EUROPE: IVD REAGENTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION) 261
TABLE 344 REST OF EUROPE: IVD REAGENTS MARKET, BY END USER, 2022–2029 (USD MILLION) 262
TABLE 345 REST OF EUROPE: CLINICAL LABORATORIES MARKET,
BY TYPE, 2022–2029 (USD MILLION) 262
TABLE 346 ASIA PACIFIC: MACROECONOMIC INDICATORS 263
TABLE 347 ASIA PACIFIC: IVD REAGENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 265
TABLE 348 ASIA PACIFIC: IVD REAGENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 265
TABLE 349 ASIA PACIFIC: ANTIBODIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 265
TABLE 350 ASIA PACIFIC: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 266
TABLE 351 ASIA PACIFIC: IVD REAGENTS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 266
TABLE 352 ASIA PACIFIC: IVD REAGENTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION) 267
TABLE 353 ASIA PACIFIC: IVD REAGENTS MARKET, BY END USER, 2022–2029 (USD MILLION) 267
TABLE 354 ASIA PACIFIC: CLINICAL LABORATORIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 267
TABLE 355 JAPAN: IVD REAGENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 269
TABLE 356 JAPAN: ANTIBODIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 269
TABLE 357 JAPAN: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 270
TABLE 358 JAPAN: IVD REAGENTS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 270
TABLE 359 JAPAN: IVD REAGENTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION) 271
TABLE 360 JAPAN: IVD REAGENTS MARKET, BY END USER, 2022–2029 (USD MILLION) 271
TABLE 361 JAPAN: CLINICAL LABORATORIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 271
TABLE 362 CHINA: IVD REAGENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 273
TABLE 363 CHINA: ANTIBODIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 273
TABLE 364 CHINA: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 274
TABLE 365 CHINA: IVD REAGENTS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 274
TABLE 366 CHINA: IVD REAGENTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION) 275
TABLE 367 CHINA: IVD REAGENTS MARKET, BY END USER, 2022–2029 (USD MILLION) 275
TABLE 368 CHINA: CLINICAL LABORATORIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 275
TABLE 369 INDIA: IVD REAGENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 277
TABLE 370 INDIA: ANTIBODIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 277
TABLE 371 INDIA: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 278
TABLE 372 INDIA: IVD REAGENTS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 278
TABLE 373 INDIA: IVD REAGENTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION) 279
TABLE 374 INDIA: IVD REAGENTS MARKET, BY END USER, 2022–2029 (USD MILLION) 279
TABLE 375 INDIA: CLINICAL LABORATORIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 279
TABLE 376 REST OF ASIA PACIFIC: IVD REAGENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 281
TABLE 377 REST OF ASIA PACIFIC: ANTIBODIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 281
TABLE 378 REST OF ASIA PACIFIC: IVD REAGENTS MARKET,
BY TECHNOLOGY, 2022–2029 (USD MILLION) 282
TABLE 379 REST OF ASIA PACIFIC: IVD REAGENTS MARKET,
BY APPLICATION, 2022–2029 (USD MILLION) 282
TABLE 380 REST OF ASIA PACIFIC: IVD REAGENTS MARKET,
BY TEST TYPE, 2022–2029 (USD MILLION) 283
TABLE 381 REST OF ASIA PACIFIC: IVD REAGENTS MARKET,
BY END USER, 2022–2029 (USD MILLION) 283
TABLE 382 REST OF ASIA PACIFIC: CLINICAL LABORATORIES MARKET,
BY TYPE, 2022–2029 (USD MILLION) 283
TABLE 383 LATIN AMERICA: MACROECONOMIC INDICATORS 284
TABLE 384 LATIN AMERICA: IVD REAGENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 284
TABLE 385 LATIN AMERICA: IVD REAGENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 285
TABLE 386 LATIN AMERICA: ANTIBODIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 285
TABLE 387 LATIN AMERICA: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 286
TABLE 388 LATIN AMERICA: IVD REAGENTS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 286
TABLE 389 LATIN AMERICA: IVD REAGENTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION) 287
TABLE 390 LATIN AMERICA: IVD REAGENTS MARKET, BY END USER, 2022–2029 (USD MILLION) 287
TABLE 391 LATIN AMERICA: CLINICAL LABORATORIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 287
TABLE 392 BRAZIL: IVD REAGENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 288
TABLE 393 BRAZIL: ANTIBODIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 289
TABLE 394 BRAZIL: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 289
TABLE 395 BRAZIL: IVD REAGENTS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 290
TABLE 396 BRAZIL: IVD REAGENTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION) 290
TABLE 397 BRAZIL: IVD REAGENTS MARKET, BY END USER, 2022–2029 (USD MILLION) 291
TABLE 398 BRAZIL: CLINICAL LABORATORIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 291
TABLE 399 MEXICO: IVD REAGENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 292
TABLE 400 MEXICO: ANTIBODIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 292
TABLE 401 MEXICO: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 293
TABLE 402 MEXICO: IVD REAGENTS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 293
TABLE 403 MEXICO: IVD REAGENTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION) 294
TABLE 404 MEXICO: IVD REAGENTS MARKET, BY END USER, 2022–2029 (USD MILLION) 294
TABLE 405 MEXICO: CLINICAL LABORATORIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 294
TABLE 406 REST OF LATIN AMERICA: IVD REAGENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 295
TABLE 407 REST OF LATIN AMERICA: ANTIBODIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 296
TABLE 408 REST OF LATIN AMERICA: IVD REAGENTS MARKET,
BY TECHNOLOGY, 2022–2029 (USD MILLION) 296
TABLE 409 REST OF LATIN AMERICA: IVD REAGENTS MARKET,
BY APPLICATION, 2022–2029 (USD MILLION) 297
TABLE 410 REST OF LATIN AMERICA: IVD REAGENTS MARKET,
BY TEST TYPE, 2022–2029 (USD MILLION) 297
TABLE 411 REST OF LATIN AMERICA: IVD REAGENTS MARKET,
BY END USER, 2022–2029 (USD MILLION) 298
TABLE 412 REST OF LATIN AMERICA: CLINICAL LABORATORIES MARKET,
BY TYPE, 2022–2029 (USD MILLION) 298
TABLE 413 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS 299
TABLE 414 MIDDLE EAST & AFRICA: IVD REAGENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 300
TABLE 415 MIDDLE EAST & AFRICA: ANTIBODIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 300
TABLE 416 MIDDLE EAST & AFRICA: IVD REAGENTS MARKET,
BY TECHNOLOGY, 2022–2029 (USD MILLION) 301
TABLE 417 MIDDLE EAST & AFRICA: IVD REAGENTS MARKET,
BY APPLICATION, 2022–2029 (USD MILLION) 301
TABLE 418 MIDDLE EAST & AFRICA: IVD REAGENTS MARKET,
BY TEST TYPE, 2022–2029 (USD MILLION) 302
TABLE 419 MIDDLE EAST & AFRICA: IVD REAGENTS MARKET,
BY END USER, 2022–2029 (USD MILLION) 302
TABLE 420 MIDDLE EAST & AFRICA: CLINICAL LABORATORIES MARKET,
BY TYPE, 2022–2029 (USD MILLION) 302
TABLE 421 GCC COUNTRIES: MACROECONOMIC INDICATORS 303
TABLE 422 GCC COUNTRIES: IVD REAGENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 304
TABLE 423 GCC COUNTRIES: IVD REAGENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 304
TABLE 424 GCC COUNTRIES: ANTIBODIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 304
TABLE 425 GCC COUNTRIES: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 305
TABLE 426 GCC COUNTRIES: IVD REAGENTS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 305
TABLE 427 GCC COUNTRIES: IVD REAGENTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION) 306
TABLE 428 GCC COUNTRIES: IVD REAGENTS MARKET, BY END USER, 2022–2029 (USD MILLION) 306
TABLE 429 GCC COUNTRIES: CLINICAL LABORATORIES MARKET,
BY TYPE, 2022–2029 (USD MILLION) 306
TABLE 430 KINGDOM OF SAUDI ARABIA: IVD REAGENTS MARKET,
BY TYPE, 2022–2029 (USD MILLION) 307
TABLE 431 KINGDOM OF SAUDI ARABIA: ANTIBODIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 308
TABLE 432 KINGDOM OF SAUDI ARABIA: IVD REAGENTS MARKET,
BY TECHNOLOGY, 2022–2029 (USD MILLION) 308
TABLE 433 KINGDOM OF SAUDI ARABIA: IVD REAGENTS MARKET,
BY APPLICATION, 2022–2029 (USD MILLION) 309
TABLE 434 KINGDOM OF SAUDI ARABIA: IVD REAGENTS MARKET,
BY TEST TYPE, 2022–2029 (USD MILLION) 309
TABLE 435 KINGDOM OF SAUDI ARABIA: IVD REAGENTS MARKET,
BY END USER, 2022–2029 (USD MILLION) 310
TABLE 436 KINGDOM OF SAUDI ARABIA: CLINICAL LABORATORIES MARKET,
BY TYPE, 2022–2029 (USD MILLION) 310
TABLE 437 UNITED ARAB EMIRATES: IVD REAGENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 311
TABLE 438 UNITED ARAB EMIRATES: ANTIBODIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 311
TABLE 439 UNITED ARAB EMIRATES: IVD REAGENTS MARKET,
BY TECHNOLOGY, 2022–2029 (USD MILLION) 312
TABLE 440 UNITED ARAB EMIRATES: IVD REAGENTS MARKET,
BY APPLICATION, 2022–2029 (USD MILLION) 312
TABLE 441 UNITED ARAB EMIRATES: IVD REAGENTS MARKET,
BY TEST TYPE, 2022–2029 (USD MILLION) 313
TABLE 442 UNITED ARAB EMIRATES: IVD REAGENTS MARKET,
BY END USER, 2022–2029 (USD MILLION) 313
TABLE 443 UNITED ARAB EMIRATES: CLINICAL LABORATORIES MARKET,
BY TYPE, 2022–2029 (USD MILLION) 313
TABLE 444 OTHER GCC COUNTRIES: IVD REAGENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 314
TABLE 445 OTHER GCC COUNTRIES: ANTIBODIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 315
TABLE 446 OTHER GCC COUNTRIES: IVD REAGENTS MARKET,
BY TECHNOLOGY, 2022–2029 (USD MILLION) 315
TABLE 447 OTHER GCC COUNTRIES: IVD REAGENTS MARKET,
BY APPLICATION, 2022–2029 (USD MILLION) 316
TABLE 448 OTHER GCC COUNTRIES: IVD REAGENTS MARKET,
BY TEST TYPE, 2022–2029 (USD MILLION) 316
TABLE 449 OTHER GCC COUNTRIES: IVD REAGENTS MARKET,
BY END USER, 2022–2029 (USD MILLION) 317
TABLE 450 OTHER GCC COUNTRIES: CLINICAL LABORATORIES MARKET,
BY TYPE, 2022–2029 (USD MILLION) 317
TABLE 451 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN IVD REAGENTS
MARKET, 2021–2023 318
TABLE 452 IVD REAGENTS MARKET: DEGREE OF COMPETITION 321
TABLE 453 IVD REAGENTS MARKET: TECHNOLOGY FOOTPRINT 328
TABLE 454 IVD REAGENTS MARKET: APPLICATION FOOTPRINT 329
TABLE 455 IVD REAGENTS MARKET: TEST TYPE FOOTPRINT 330
TABLE 456 IVD REAGENTS MARKET: REGION FOOTPRINT 331
TABLE 457 IVD REAGENTS MARKET: DETAILED LIST OF KEY STARTUPS/SMES 334
TABLE 458 IVD REAGENTS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES 334
TABLE 459 IVD REAGENTS MARKET: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2021–SEPTEMBER 2024 335
TABLE 460 IVD REAGENTS MARKET: DEALS, JANUARY 2021–SEPTEMBER 2024 336
TABLE 461 IVD REAGENTS MARKET: EXPANSIONS, JANUARY 2021–SEPTEMBER 2024 337
TABLE 462 IVD REAGENTS MARKET: OTHER DEVELOPMENTS, JANUARY 2021–SEPTEMBER 2024 337
TABLE 463 DANAHER CORPORATION: COMPANY OVERVIEW 338
TABLE 464 DANAHER CORPORATION: PRODUCTS OFFERED 339
TABLE 465 DANAHER CORPORATION: DEALS, JANUARY 2021–SEPTEMBER 2024 340
TABLE 466 DANAHER CORPORATION: EXPANSIONS, JANUARY 2021–SEPTEMBER 2024 340
TABLE 467 DANAHER CORPORATION: OTHER DEVELOPMENTS, JANUARY 2021–SEPTEMBER 2024 340
TABLE 468 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW 342
TABLE 469 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED 343
TABLE 470 F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2021–SEPTEMBER 2024 344
TABLE 471 ABBOTT: COMPANY OVERVIEW 346
TABLE 472 ABBOTT: PRODUCTS OFFERED 347
TABLE 473 ABBOTT: DEALS, JANUARY 2021–SEPTEMBER 2024 348
TABLE 474 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW 350
TABLE 475 SIEMENS HEALTHINEERS AG: PRODUCTS OFFERED 351
TABLE 476 SIEMENS HEALTHINEERS AG: DEALS, JANUARY 2021–SEPTEMBER 2024 352
TABLE 477 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 354
TABLE 478 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED 355
TABLE 479 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021–SEPTEMBER 2024 356
TABLE 480 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2021–SEPTEMBER 2024 357
TABLE 481 ILLUMINA, INC.: COMPANY OVERVIEW 359
TABLE 482 ILLUMINA, INC.: PRODUCTS OFFERED 360
TABLE 483 ILLUMINA, INC.: DEALS, JANUARY 2021–SEPTEMBER 2024 361
TABLE 484 BIOMÉRIEUX: COMPANY OVERVIEW 362
TABLE 485 BIOMÉRIEUX: PRODUCTS OFFERED 363
TABLE 486 BIOMÉRIEUX: DEALS, JANUARY 2021–SEPTEMBER 2024 364
TABLE 487 BD: COMPANY OVERVIEW 365
TABLE 488 BD: PRODUCTS OFFERED 367
TABLE 489 BD: DEALS, JANUARY 2021–SEPTEMBER 2024 367
TABLE 490 HOLOGIC, INC.: COMPANY OVERVIEW 368
TABLE 491 HOLOGIC, INC.: PRODUCTS OFFERED 370
TABLE 492 HOLOGIC, INC.: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2021–SEPTEMBER 2024 371
TABLE 493 HOLOGIC, INC.: DEALS, JANUARY 2021–SEPTEMBER 2024 371
TABLE 494 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW 372
TABLE 495 BIO-RAD LABORATORIES, INC.: PRODUCTS OFFERED 374
TABLE 496 BIO-RAD LABORATORIES, INC.: DEALS, JANUARY 2021–SEPTEMBER 2024 374
TABLE 497 SYSMEX CORPORATION: COMPANY OVERVIEW 375
TABLE 498 SYSMEX CORPORATION: PRODUCTS OFFERED 376
TABLE 499 SYSMEX CORPORATION: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2021–SEPTEMBER 2024 377
TABLE 500 SYSMEX CORPORATION: DEALS, JANUARY 2021–SEPTEMBER 2024 377
TABLE 501 SYSMEX CORPORATION: EXPANSIONS, JANUARY 2021–SEPTEMBER 2024 377
TABLE 502 QIAGEN N.V.: COMPANY OVERVIEW 378
TABLE 503 QIAGEN N.V.: PRODUCTS OFFERED 379
TABLE 504 QIAGEN N.V.: DEALS, JANUARY 2021–SEPTEMBER 2024 380
TABLE 505 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW 381
TABLE 506 AGILENT TECHNOLOGIES, INC.: PRODUCTS OFFERED 383
TABLE 507 AGILENT TECHNOLOGIES, INC.: DEALS, JANUARY 2021–SEPTEMBER 2024 384
TABLE 508 AGILENT TECHNOLOGIES, INC.: EXPANSIONS, JANUARY 2021–SEPTEMBER 2024 384
TABLE 509 REVVITY: COMPANY OVERVIEW 385
TABLE 510 REVVITY: PRODUCTS OFFERED 386
TABLE 511 REVVITY: DEALS, JANUARY 2021–SEPTEMBER 2024 387
TABLE 512 REVVITY: OTHER DEVELOPMENTS, JANUARY 2021–SEPTEMBER 2024 387
TABLE 513 DIASORIN S.P.A.: COMPANY OVERVIEW 388
TABLE 514 DIASORIN S.P.A.: PRODUCTS OFFERED 389
TABLE 515 DIASORIN S.P.A.: DEALS, JANUARY 2021–SEPTEMBER 2024 391
TABLE 516 GRIFOLS S.A.: COMPANY OVERVIEW 392
TABLE 517 GRIFOLS S.A.: PRODUCTS OFFERED 393
TABLE 518 GRIFOLS S.A.: DEALS, JANUARY 2021–SEPTEMBER 2024 394
TABLE 519 WERFEN, S.A.: COMPANY OVERVIEW 395
TABLE 520 WERFEN, S.A.: PRODUCTS OFFERED 396
TABLE 521 WERFEN, S.A.: DEALS, JANUARY 2021–SEPTEMBER 2024 397
TABLE 522 QUIDELORTHO CORPORATION: COMPANY OVERVIEW 398
TABLE 523 QUIDELORTHO CORPORATION: PRODUCTS OFFERED 400
TABLE 524 QUIDELORTHO CORPORATION: DEALS, JANUARY 2021–SEPTEMBER 2024 401
TABLE 525 QUIDELORTHO CORPORATION: EXPANSIONS, JANUARY 2021–SEPTEMBER 2024 401
TABLE 526 CHEMBIO DIAGNOSTICS, INC.: COMPANY OVERVIEW 402
TABLE 527 CHEMBIO DIAGNOSTICS, INC.: PRODUCTS OFFERED 403
TABLE 528 SURMODICS, INC.: COMPANY OVERVIEW 404
TABLE 529 SURMODICS, INC.: PRODUCTS OFFERED 406
TABLE 530 MERCK KGAA: COMPANY OVERVIEW 407
TABLE 531 MERCK KGAA: PRODUCTS OFFERED 408
TABLE 532 MEDICAL & BIOLOGICAL LABORATORIES CO., LTD.: COMPANY OVERVIEW 410
TABLE 533 CANVAX: COMPANY OVERVIEW 411
TABLE 534 PRESTIGE DIAGNOSTICS: COMPANY OVERVIEW 412
TABLE 535 ADALTIS S.R.L.: COMPANY OVERVIEW 413
TABLE 536 RANDOX LABORATORIES LTD.: COMPANY OVERVIEW 414
LIST OF FIGURES
FIGURE 1 IVD REAGENTS MARKET SEGMENTATION AND REGIONAL SCOPE 39
FIGURE 2 IVD REAGENTS MARKET: RESEARCH DESIGN 42
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 47
FIGURE 4 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH 48
FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 49
FIGURE 6 IVD REAGENTS MARKET: TOP-DOWN APPROACH 50
FIGURE 7 DATA TRIANGULATION METHODOLOGY 51
FIGURE 8 IVD REAGENTS MARKET, BY TYPE, 2024–2029 (USD MILLION) 54
FIGURE 9 IVD REAGENTS MARKET, BY TECHNOLOGY, 2024–2029 (USD MILLION) 55
FIGURE 10 IVD REAGENTS MARKET, BY APPLICATION, 2024–2029 (USD MILLION) 56
FIGURE 11 IVD REAGENTS MARKET, BY TEST TYPE, 2024–2029 (USD MILLION) 57
FIGURE 12 IVD REAGENTS MARKET, BY END USER, 2024–2029 (USD MILLION) 57
FIGURE 13 IVD REAGENTS MARKET, BY REGION, 2024–2029 (USD MILLION) 58
FIGURE 14 INCREASING PREVALENCE OF CHRONIC AND INFECTIOUS DISEASES TO DRIVE MARKET 59
FIGURE 15 CHINA TO LEAD MARKET DURING FORECAST PERIOD 60
FIGURE 16 US AND LABORATORY TESTS SEGMENT ACCOUNTED FOR LARGEST SHARE OF
NORTH AMERICAN IVD REAGENTS MARKET IN 2023 60
FIGURE 17 CHINA TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD 61
FIGURE 18 IVD REAGENTS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 62
FIGURE 19 CRITICAL IMPACT AREAS OF IVD REAGENTS 69
FIGURE 20 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 74
FIGURE 21 IVD REAGENTS MARKET: VALUE CHAIN ANALYSIS 78
FIGURE 22 IVD REAGENTS MARKET: SUPPLY CHAIN ANALYSIS 79
FIGURE 23 IVD REAGENTS MARKET: ECOSYSTEM ANALYSIS 80
FIGURE 24 IVD REAGENTS MARKET: INVESTMENT AND FUNDING SCENARIO, 2019−2024 81
FIGURE 25 IVD REAGENTS MARKET: PATENT ANALYSIS, JANUARY 2014–MARCH 2024 84
FIGURE 26 IVD REAGENTS MARKET: PORTER’S FIVE FORCES ANALYSIS 87
FIGURE 27 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF IVD REAGENTS, BY END USER 97
FIGURE 28 KEY BUYING CRITERIA FOR IVD REAGENTS, BY END USER 98
FIGURE 29 NORTH AMERICA: IVD REAGENTS MARKET SNAPSHOT 222
FIGURE 30 ASIA PACIFIC: IVD REAGENTS MARKET SNAPSHOT 264
FIGURE 31 IVD REAGENTS MARKET: REVENUE ANALYSIS OF KEY PLAYERS,
2021–2023 (USD MILLION) 320
FIGURE 32 IVD REAGENTS MARKET SHARE ANALYSIS OF KEY PLAYERS, 2023 320
FIGURE 33 FINANCIAL METRICS 322
FIGURE 34 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF
KEY VENDORS, (2021–2023) 323
FIGURE 35 IVD REAGENTS MARKET: BRAND/PRODUCT COMPARISON 324
FIGURE 36 IVD REAGENTS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023 326
FIGURE 37 IVD REAGENTS MARKET: COMPANY FOOTPRINT 327
FIGURE 38 IVD REAGENTS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023 333
FIGURE 39 DANAHER CORPORATION: COMPANY SNAPSHOT (2023) 339
FIGURE 40 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2023) 343
FIGURE 41 ABBOTT: COMPANY SNAPSHOT (2023) 347
FIGURE 42 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2023) 351
FIGURE 43 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2023) 355
FIGURE 44 ILLUMINA, INC.: COMPANY SNAPSHOT (2023) 360
FIGURE 45 BIOMÉRIEUX: COMPANY SNAPSHOT (2023) 363
FIGURE 46 BD: COMPANY SNAPSHOT (2023) 366
FIGURE 47 HOLOGIC, INC.: COMPANY SNAPSHOT (2023) 369
FIGURE 48 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2023) 373
FIGURE 49 SYSMEX CORPORATION: COMPANY SNAPSHOT (2022) 376
FIGURE 50 QIAGEN N.V.: COMPANY SNAPSHOT (2023) 379
FIGURE 51 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2023) 382
FIGURE 52 REVVITY: COMPANY SNAPSHOT (2023) 386
FIGURE 53 DIASORIN S.P.A.: COMPANY SNAPSHOT (2023) 389
FIGURE 54 GRIFOLS S.A.: COMPANY SNAPSHOT (2023) 393
FIGURE 55 WERFEN, S.A.: COMPANY SNAPSHOT (2023) 396
FIGURE 56 QUIDELORTHO CORPORATION: COMPANY SNAPSHOT (2023) 399
FIGURE 57 CHEMBIO DIAGNOSTICS, INC.: COMPANY SNAPSHOT (2022) 402
FIGURE 58 SURMODICS, INC.: COMPANY SNAPSHOT (2023) 405
FIGURE 59 MERCK KGAA: COMPANY SNAPSHOT (2023) 408
MarketsandMarkets（マーケッツアンドマーケッツ）は世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。広範な市場を対象にした市場調査レポートを出版しています。
※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。
ライセンス別価格表
調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。
ライセンスタイプ1
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD4,950 | USD6,650 | USD8,150 | USD10,000 |
ライセンスタイプ2
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD7,150 | USD8,500 | USD9,650 | USD11,000 |
ライセンスタイプ3
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD8,150 | お問合せください | お問合せください | お問合せください |
ライセンスタイプ4
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD9,000 | USD10,500 | USD12,000 | USD13,500 |
ミニレポート ※定性調査にフォーカスした調査レポートです。詳細はお問合せください。
| シングルユーザ | コーポレート |
| USD 2,650 | USD 4,250 |
ご購入に関するご案内
価格・納期について
- 価格
- ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
- ライセンス
- シングルユーザライセンス
- 1名のみレポートファイルのご利用が可能です。
- マルチユーザライセンス
- 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
- コーポレートライセンス
- 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
- エンタープライズサイトライセンス
- 特別ライセンスです。適用範囲についてはお問合せください。
- シングルユーザライセンス
- 納品形態
- Eメール
- 納期
- 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）
ご注文方法
- レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。
その他
- 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。
株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。
最新調査レポート
- 自動車用アラミド繊維市場規模、シェア、動向、2030年までの世界予測 2025-12-15
- ポリヒドロキシアルカノエート (PHA) 市場規模、シェア、動向、2030年までの世界予測 2025-12-15
- 複合輸送市場規模、シェア、動向、2032年までの世界予測 2025-12-12
- 有機酸市場規模、シェア、動向、2030年までの世界予測 2025-12-11
- ハイブリッドボンディング市場規模、シェア、動向、2032年までの世界予測 2025-12-11